These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34530804)

  • 21. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-12.
    Iqbal S; Shi J; Seib K; Lewis P; Moro PL; Woo EJ; Shimabukuro T; Orenstein WA
    Lancet Infect Dis; 2015 Oct; 15(10):1175-1182. PubMed ID: 26289956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015.
    Haber P; Moro PL; Ng C; Lewis PW; Hibbs B; Schillie SF; Nelson NP; Li R; Stewart B; Cano MV
    Vaccine; 2018 Jan; 36(4):559-564. PubMed ID: 29241647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Willingness to receive a vaccine is influenced by adverse events following immunisation experienced by others.
    Christou-Ergos M; Wiley KE; Leask J
    Vaccine; 2023 Jan; 41(1):246-250. PubMed ID: 36446655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.
    Moro PL; Zhang B; Ennulat C; Harris M; McVey R; Woody G; Marquez P; McNeil MM; Su JR
    Vaccine; 2023 Mar; 41(11):1859-1863. PubMed ID: 36669964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mapping the Cognitive Biases Related to Vaccination: A Scoping Review of the Literature.
    Raj A; Singh AK; Wagner AL; Boulton ML
    Vaccines (Basel); 2023 Dec; 11(12):. PubMed ID: 38140241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the Vaccine Adverse Event Reporting System (VAERS), United States, October 2011-July 2018.
    McNeil MM; Paradowska-Stankiewicz I; Miller ER; Marquez PL; Seshadri S; Collins LC; Cano MV
    Vaccine; 2019 Oct; 37(44):6760-6767. PubMed ID: 31548014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imprecision in adverse event reports following immunization against HPV in Japan and COVID-19 in the USA, UK, and Japan-and the effects of vaccine hesitancy and government policy.
    Inokuma Y; Kneller R
    Eur J Clin Pharmacol; 2023 Feb; 79(2):269-278. PubMed ID: 36527455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of cognitive biases with human papillomavirus vaccine hesitancy: a cross-sectional study.
    Pomares TD; Buttenheim AM; Amin AB; Joyce CM; Porter RM; Bednarczyk RA; Omer SB
    Hum Vaccin Immunother; 2020 May; 16(5):1018-1023. PubMed ID: 31859593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety profile of
    Puente Gómez I; Verheust C; Hanssens L; Dolhain J
    Expert Rev Vaccines; 2020 Aug; 19(8):771-779. PubMed ID: 32729745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.
    McMahon AW; Iskander J; Haber P; Chang S; Woo EJ; Braun MM; Ball R
    Pediatrics; 2005 Feb; 115(2):453-60. PubMed ID: 15687455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Updates on Vaccine Safety and Post-Licensure Surveillance for Adverse Events Following Immunization in South Korea, 2005-2017.
    Yoon D; Kim JH; Lee H; Shin JY
    Yonsei Med J; 2020 Jul; 61(7):623-630. PubMed ID: 32608206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS).
    Braun MM; Mootrey GT; Salive ME; Chen RT; Ellenberg SS
    Pediatrics; 2000 Oct; 106(4):E51. PubMed ID: 11015546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).
    Sever JL; Brenner AI; Gale AD; Lyle JM; Moulton LH; Ward BJ; West DJ
    Pharmacoepidemiol Drug Saf; 2004 Dec; 13(12):825-40. PubMed ID: 15386719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ⩾19years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012-December 31, 2015.
    Haber P; Arana J; Pilishvili T; Lewis P; Moro PL; Cano M
    Vaccine; 2016 Dec; 34(50):6330-6334. PubMed ID: 27836437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000-2015.
    Lei J; Balakrishnan MR; Gidudu JF; Zuber PLF
    Vaccine; 2018 Mar; 36(12):1577-1582. PubMed ID: 29454518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse events after tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine administered to adults 65 years of age and older reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2010.
    Moro PL; Yue X; Lewis P; Haber P; Broder K
    Vaccine; 2011 Nov; 29(50):9404-8. PubMed ID: 21920404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).
    Sever JL; Brenner AI; Gale AD; Lyle JM; Moulton LH; West DJ;
    Pharmacoepidemiol Drug Saf; 2002; 11(3):189-202. PubMed ID: 12051118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009-2010 season in the active component U.S. military and civilians aged 17-44years reported to the Vaccine Adverse Event Reporting System.
    Bardenheier BH; Duderstadt SK; Engler RJ; McNeil MM
    Vaccine; 2016 Aug; 34(37):4406-14. PubMed ID: 27449076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse events following immunization: Findings from 2017/2018 measles vaccination campaign, Nigeria AEFI reporting in 2017/2018 measles vaccination campaign.
    Gbenewei E; Nomhwange T; Taiwo L; Ayodeji I; Yusuf K; Jean Baptiste AE; Nsubuga P; Braka F; Oteri J; Shuaib F
    Vaccine; 2021 Nov; 39 Suppl 3():C82-C88. PubMed ID: 33714655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determinants of COVID-19 vaccine-induced myocarditis.
    Rose J; Hulscher N; McCullough PA
    Ther Adv Drug Saf; 2024; 15():20420986241226566. PubMed ID: 38293564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.